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Abstract  
Introduction: This study aims at describing the epidemiological and clinical characteristics, severity, reversibility testing and response to 
treatment using simple spirometry in asthmatic patients attending a model specialized Asthma Care Center. Methods: Eligible subjects must have 
a suggestive clinical picture and confirmed by spirometry to have a 12% plus 200ml absolute increase in FEV1 either by reversibility testing or after 
a therapeutic trial with inhaled and/or oral steroid therapy. Budesonide-Formoterol Turbohaler was used for reversibility testing and for 
maintenance therapy with or without the addition of oral prednisolone. Results: One hundred and nineteen patients were eligible for the study. 
Age ranged between 10 -70 years. One hundred and thirteen patients (95.0%) had an FEV1 less than 80% of predicted. One hundred and five 
patients (88.2%) had reversibility testing of whom 72 (68.6%) had a significant reversibility. Sixty two patients (52.1%) were prescribed 
Budesonide-Formoterol Turbohaler only whilst 57 were prescribed both Budesonide-Formoterol Turbohaler and oral prednisolone. Patients were 
reviewed after a mean of 14.9 days (range 6.0-28.0). Seventy two patients (60.5%) had increased their FEV1 to more than 80% of their predicted 
value. By logistic regression analysis, predicted FEV1 at baseline was a significant negative predictor of a complete response. Conclusion: Most 
patients had abnormal spirometry with more than half having an FEV1 that is 60% or less of their predicted normal reading. Reversibility testing 
using Budesonide-Formoterol Turbohaler confirmed the fast onset of action of its Formoterol component and helped in cutting the cost of this test. 
The majority improved with treatment with 60% normalizing their spirometry highlighting the feasibility and applicability of specialized asthma care 
centers in resource-poor countries. 
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Introduction 
 
The global burden of Bronchial Asthma (BA) particularly in 
developing countries is on the increase [1,2]. Approximately 300 
million people worldwide have asthma, and its prevalence seems to 
increase by approximately 50% every ten years [1,2]. BA is not a 
benign disease and has clearly had a serious impact on national 
health care systems expenditure in developed countries, patient's 
quality of life and more importantly has a noteworthy mortality risk 
[1-4]. International asthma guidelines emphasize the importance of 
a comprehensive asthma care delivery service [5]. All guidelines 
highlight the importance of proper diagnosis of BA, individualized 
therapeutic interventions based on assessment of its severity, 
patient education and regular follow-up. Despite the accessibility 
and availability of these guidelines on the World Wide Web, BA care 
remains suboptimal in many countries [1]. In Khartoum, the Capital 
of Sudan we established an Asthma Care Center aiming to provide a 
higher quality asthma care service. Structured care, patient 
education and spirometry were its pillars. All patients were 
prescribed and thoroughly educated on either breath-activated 
devices or metered dose inhalers administered via spacer devices. 
In this study we investigated the outcome of our intervention in the 
subgroup of patients who were prescribed Budesonide-Formoterol 
Turbohaler (BFT) (160 ug/4.5 ug). This investigation aims to 
describe the epidemiological characteristics and define by simple 
spirometry the severity, reversibility and spirometric response to 
treatment with BFT in a cohort of Sudanese patients with Bronchial 
Asthma. The clinical efficacy and cost-effectiveness of BFT in 
chronic asthma care is well documented [6,7]. Inhaled Formoterol- 
a long acting beta 2 agonist with a fast onset of action and kinetics 
similar to inhaled salbutamol [8,9] is used for reversibility testing. 
The rationale for its use as such are first to help relief patients of 
their symptoms before leaving the clinic, secondly as an opportunity 
to train patients on inhaler technique and possibly improve 
compliance as patients note the immediate effectiveness of their 













A retrospective chart review of patients with Bronchial Asthma. 
Patient's consent was not sought as this was a retrospective chart 





This study was undertaken in a dedicated Bronchial Asthma Care 
Center in Khartoum, Sudan. The center is manned by a Consultant 
Pulmonologist, Asthma Educator/Spirometry technician and a Clerk. 
  
Patients and medications 
  
Patients attending the center with a clinical picture suggestive of 
Bronchial Asthma who were prescribed BFT and who were 
confirmed by spirometry to have a 12% increase plus 200 ml 
absolute increase in FEV1 after reversibility testing or after a steroid 
trial were eligible for inclusion in the study. A steroid trial was with 
inhaled steroid (budesonide 320 ug twice daily by turbohaler in 
Budesonide-Formoterol Turbohaler) for two weeks with or without 
oral prednisolone 30 mg per day for 5 days. Patients unable to do 
spirometry or have poor technique were excluded. Patients with a 
diagnosis of bronchiectasis, COPD or other respiratory diseases were 
also excluded. Patients were seen by one Pulmonologist. A detailed 
history is taken along a pre-specified and unified format detailing all 
the essential historical data pertaining to Bronchial Asthma. Patients 
were then seen by the Asthma Educator/Spirometry technician who 
performed baseline spirometry (hand-held spirometer -Spirodoc-
GIMA) and educated the patients on their illness and their inhaler 
technique. Spirometry was performed with the patient sitting. The 
first two puffs of their BFT were then administered and spirometry 
repeated 15 minutes later. Patients must be able to have three 
attempts at spirometry with variations of less than 0.1 liter in FEV1 
between the two best readings for a reliable trace. Most patients 
were requested to re-attend clinic in 2 weeks for clinical 
reassessment and spirometry. However, those attending up to 4 
weeks post first visit were included. As normative spirometric data 
for Sudanese subjects are not available and these are generally 
believed to be 10 percent lower than those of Caucasian, Caucasian 
FEV1 data corrected by deducting 10% were utilized. Data was 
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entered on a Minitab 15 spreadsheet for analysis. Simple descriptive 
statistical tests were used together with the 2-Sample t-test, Chi 
square test and logistic regression analysis as appropriate to test for 
significance and associations. A p-value of less than 0.05 is 





One hundred and nineteen patients were eligible for the study. Sixty 
two were male and 57 were female with an average age of 30.5 
(range 10-70) and 30.3 (range 10-68) years respectively. Mean 
body mass index was 23.2 (range 11.8-33.2) for males and 27.4 
(range 14.3-44.1) for females. A BMI of more than 30 was more 
frequent in females (20) versus (6) in males (Chi Square Test p 
value= 0.001). Ninety patients (75.6%) were previously diagnosed 
as having bronchial asthma. Mean duration of asthma for male 
patients was 156.9 months (range 6-720 months) and for females 
was 191.4 months (range 1.2-600 months). Twenty four of the 
known asthmatic patients (26.7%) have never been prescribed 
inhaler therapy before. The mean duration of asthma for this group 
was 156 months (range 1.2-540 months). Family history in first 
degree relatives for asthma was positive in 73.9% of patients. Of 66 
patients who could describe their inhalers, thirty nine (59.1%) were 
on a steroid inhaler. Twenty patients (16.9%) were active or 
previous smokers. Eleven patients reported an allergic reaction to 




Cough and shortness of breath were the commonest symptoms and 
were reported by 112 patients (94.1%). Wheeze was reported by 98 
patients (85.2%). Eighty patients (72.1%) had productive cough. 
  
Gastro-esophageal and Upper Respiratory Symptoms 
  
Forty patients (35.7%) admitted to have frequent heartburn and 64 
patients (54.7%) reported symptoms suggestive of allergic rhinitis 
and/or postnasal drip. Those with gastro-esophageal reflux disease 
(GERD) symptoms had a lower percent predicted FEV1 than those 
without, but this did not reach statistical significance: 52.0% vs 
57.7% (Two-sample t-test p= 0.10). Percent FEV1 readings were 
comparable in those with and those without upper respiratory 
symptoms: 54.8% versus 56.0 % (Two-sample t-test p= 0.72). 
Wheeze on examination 
  
On auscultation 84 (70.6%) patients had audible wheeze. 
  
Baseline FEV1 and Severity Classification (Table 2) 
  
Mean FEV1 at baseline was 1.8 L (range 0.6-3.2L) for males and 1.5 
L (range 0.5-2.4L) for females. Expressed as a percent of the 
predicted normal values, mean FEV1 in males was 52.9% (range 
18.7-87.7%) and for females was 57.9% (range 14.5-85.6%). 
Wheezy patients had a significantly lower predicted FEV1 than those 
with no audible wheeze: 50.4% versus 67.1% (Two sample t test p 
value< 0.0001). One hundred and thirteen patients (95.0%) had an 
FEV1 less than 80% of predicted and 68 (57.1%) had a reading that 
is less than 60% of predicted. Eight (11.8%) of the latter group did 
not have audible wheeze on auscultation. 
  
BFT reversibility testing (Table 2, Figure 1) 
  
One hundred and five patients (88.2%) had reversibility testing of 
whom 72 (68.6%) had a significant change of 12% plus 200 ml 
increase in FEV1. The average percent increase in FEV1 in this 
group was 30.1% (range 12.1-71.8%) with a mean absolute 
increase of 442.6 mls (range 200-1130 mls). All of those who did 
not have an initial reversibility testing (14) and those who did not 
attain a significant change after Formoterol (33) did achieve a 12% 
plus 200 ml increase following their course of treatment. Mean 
percentage increase in FEV1 was 65.5% (range 13.4-297.0%) with 
an absolute mean increase of 746.6 mls (range 230.0-2200mls). 
Prescribed Medications and Symptomatic Response to Therapy Sixty 
two patients (52.1%) were prescribed BFT only whilst 57 were 
prescribed both BFT and oral prednisolone. Of the latter group, 48 
patients (84.2%) had an FEV1 of less than 60% of predicted. 
Patients were reviewed after a mean of 14.9 days (range 6.0-28.0). 
On their second visit, 118 reported that their symptoms improved 
(99.2%) of whom 74 (62.2%) said their symptoms have 
disappeared or much improved. 
  
Spirometric Response to Therapy (Table 2, Figure 2 and Figure 
3) The average FEV1 reading post treatment was 2.6 L in males 
(range 1.1-4.8) and 2.2 L in females (range 1.0-2.9). The respective 
average percent increase in FEV1 were 65.4% (-1.7-300%) and 
59.7% (range 11.7-274%). Expressed as a percent of their 
predicted normal values, mean FEV1 in males has increased from 
52.9% to 79.1% and for females from 57.9% to 85.7%. Mean 
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percentage FEV1 increase in the BFT group was 33.7% (range -
1.74-167.9) compared to 94.2% (range 6.9-300) in the BFT plus 
oral prednisolone group (two-sample t-test p<0.0001). Seventy two 
patients (60.5%) had increased their FEV1 to more than 80% of 
their predicted value i.e. normalized their spirometry. 
  
Predictors of Complete Response (Table 3) 
  
The mean percent increase in FEV1 in those who normalized their 
FEV1 as opposed to those who did not were 62.5% (range 13.4-
300) and 63.0% (range -1.7-292.5) respectively (Two-sample t-test 
p=0.82). By logistic regression analysis, predicted FEV1 at baseline 
was a significant negative predictor of a complete response with 
age, duration of asthma and initial FEV1 change to reversibility 
testing having no such correlation. Forty six patients who were 
prescribed BFT normalized their spirometry compared to 26 patients 
who were prescribed BFT plus oral prednisolone (Chi Square test p= 
0.001). Mean percent FEV1 of predicted at baseline was 66.6% for 





An initial striking feature in this study is the extremely low baseline 
spirometric readings of this cohort of patients. This highlights the 
deficiency of care this cohort of patients was receiving. Anti-
inflammatory therapy is the mainstay of treatment of Bronchial 
Asthma [5]. More than a quarter of the known asthmatics were not 
on inhaler therapy and more than a third were not on steroid 
inhalers. Furthermore, what we have very frequently observed is the 
very poor inhaler technique in these patients. This has previously 
been documented in a study in the main respiratory hospital in 
Khartoum where 82% of patients had poor inhaler technique [10]. 
This finding emphasizes the importance of patient education on 
their inhaler devices. This latter service has been one of the major 
objectives and strength in our asthma care center service. The use 
of BFT in our cohort was in accordance with Global Initiative for 
Asthma (GINA) guideline recommendation as the majority had 
relatively severe and highly symptomatic asthma [5]. 
  
The presence of audible wheeze on examination was clearly a 
marker of severity as these patients on the whole, had a 
significantly lower predicted FEV1 readings. However, almost a third 
of this cohort of asthmatic patients had no wheeze on examination 
including no less than 10% of those with the more severe 
spirometry readings. Spirometric assessment of suspected patients 
with Bronchial Asthma is thus extremely vital for quality care. 
Obesity is seen in a proportion of our patients specially females. As 
is known, obesity is a risk factor for asthma and is also associated 
with poor asthma control and needs to be properly managed by 
dieting and weight reduction [11]. Almost a third of our patients 
admitted to having frequent GERD symptoms and more than a half 
to upper respiratory symptoms. FEV1 in those with GERD were 
clearly worse than in those without implying a causal or contributory 
effect and underscoring the importance of inquiring about and 
managing GERD symptoms [12,13]. All our patients with GERD were 
prescribed proton-pump inhibitors and were given life style 
modification advice. Of interest is the reported food allergy to 
Aubergine (Black Egg Plant) that is seen in our cohort. This seems 
to be the commonest “food allergen” that is implicated in adult 
Sudanese patients with asthma. However, there is a debate on 
whether this represents a true allergic response to constituent 
protein products or a non-allergic pharmacologic reaction to 
histamine-like and other components of the eggplant [14,15]. These 
reactions are reported to be more prevalent in atopic individuals 
[14,15]. 
  
Almost three-quarters of our patients had significant increases in 
FEV1 after reversibility testing. The use of the prescribed medication 
(BFT) for reversibility testing assisted us in realizing many goals of 
our service. The need of using salbutamol MDI via spacer or 
nebulizer for testing was no longer required. This meant that we 
were able to save on reagent cost (Salbutamol MDI or nebulizer 
solution) and spacer devices or nebulizer machine use (unit price 
plus sterilizing between patients). We had more time to educate 
these patients on their inhaler device use instead of training on MDI 
via spacer etc. use for reversibility testing. We were very pleased to 
see very symptomatic and breathless patients feeling already 
improved following the use of their new medication and before 
leaving clinic. We hoped that this will translate into better patient 
compliance. 
  
The outcome of our interventions was similarly very satisfactory. 
Almost all of our patients reported improvements in their symptoms 
and a good proportion had become asymptomatic or remarked that 
they were much improved. This was mirrored by the large 
improvements in the patient’s FEV1. More than 60% of patients 
normalized their FEV1. The most important (negative) predictor of 
FEV1 normalization was the baseline reading. Patients with very 
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poor spirometric figures were less likely to achieve their target 
normal reading. Patients with incomplete responses had, albeit non-
significant difference, a longer duration of Bronchial Asthma. This 
emphasizes the importance of early diagnosis and proper asthma 
care interventions [16,17]. Addition of systemic steroids to BFT in 
those with FEV1 readings below 60% of predicted was prudent as it 
has clearly lead to a more satisfactory, significant and worthwhile 
improvement in spirometry. More patients on BFT alone normalized 
their FEV1 compared to those on BFT and prednisolone. This is 
clearly a reflection of the lower baseline FEV1 readings in the latter 





In summary, our objectives of providing a satisfactory dedicated 
service to asthma patients were fulfilled. The use of BFT for an 
average of two-weeks with or without oral prednisolone was 
effective in improving the symptoms in almost all of our patients 
who were prescribed this inhaler. Furthermore, a good proportion 
(60%) normalized their spirometry. Those with very poor FEV1 
readings at the outset (more than 50% of our cohort) were less 
likely to normalize their spirometry. The magnitude of improvement 
in FEV1 was appreciable in all grades of severity provided that oral 
prednisolone is added to BFT in those with FEV1 of less than 60% 
of predicted. The importance of routine spirometry in Bronchial 
Asthma care particularly in severity assessment and choice of 
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Gender 119 62 57 












Smoking 20 (16.8%) 18 2 
PH of B Asthma 90 (75.6%) 48 42 






Cough 112 (94.1%) 
  
Sputuma 80 (72.1%) 
  
SOB 112 (94.1%) 
  
Wheezeb 98 (85.2%) 
  






Family History of Asthma 88 (73.9%) 
  
Previous Use of Inhalers 66 (73.3%) 
  
Previous Use of Steroid Inhalers 39 (59.1%) 
  
Missing data: a: 7 patients, b: 4 patients, c: 7 patients, d: 2 patients 
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Table 3: Complete and incomplete responders comparison table 

























































Figure 1: Effect of budesonide/formoterol on fev1 after reversibility testing 
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Figure 3: Number and percent of asthmatic patients with normal fev1 before and after treatment 
 
